ScoreWhy is Senores Pharmaceuticals Ltd ?
1
Company has a Debt to Equity ratio (avg) of 0.10 times
2
Healthy long term growth as Net Sales has grown by an annual rate of 71.70% and Operating profit at 108.34%
3
The company has declared Positive results for the last 4 consecutive quarters
- PAT(Latest six months) At Rs 63.27 cr has Grown at 80.72%
- NET SALES(Q) Highest at Rs 175.19 cr
4
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 0.59% over the previous quarter and collectively hold 13.25% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
5
Market Beating Performance
- Even though the market (BSE500) has generated negative returns of -0.13% in the last 1 year, the stock has been able to generate 125.20% returns
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Senores Pharma. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Senores Pharma. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Senores Pharma.
124.63%
3.11
40.16%
Sensex
-6.64%
-0.51
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
71.70%
EBIT Growth (5y)
108.34%
EBIT to Interest (avg)
4.69
Debt to EBITDA (avg)
3.61
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.42
Tax Ratio
23.62%
Dividend Payout Ratio
0
Pledged Shares
1.90%
Institutional Holding
13.25%
ROCE (avg)
9.51%
ROE (avg)
9.90%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
45
Industry P/E
34
Price to Book Value
5.51
EV to EBIT
35.44
EV to EBITDA
29.34
EV to Capital Employed
4.77
EV to Sales
8.25
PEG Ratio
0.46
Dividend Yield
NA
ROCE (Latest)
13.47%
ROE (Latest)
12.36%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
PAT(Latest six months)
At Rs 63.27 cr has Grown at 80.72%
NET SALES(Q)
Highest at Rs 175.19 cr
-9What is not working for the Company
INTEREST(Q)
Highest at Rs 8.46 cr
NON-OPERATING INCOME(Q)
is 37.28 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Senores Pharma.
Profit After Tax (PAT) - Latest six months
At Rs 63.27 cr has Grown at 80.72%
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 175.19 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Here's what is not working for Senores Pharma.
Interest - Quarterly
At Rs 8.46 cr has Grown at 58.72%
Quarter on Quarter (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Interest - Quarterly
Highest at Rs 8.46 cr
in the last five quarters and Increased by 58.72 % (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Non Operating Income - Quarterly
is 37.28 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
Non Operating Income - Quarterly
Highest at Rs 17.67 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
